Advisory Research’s Cue Biopharma CUE Stock Holding History

Advisory Research’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$271K	Sell	8,573 -1	-0%	-$23	0.03%	133
2026 Q1	$59.1K	Hold	8,574	–	–	0.01%	137
2025 Q4	$78.6K	Hold	8,574	–	–	0.01%	142
2025 Q3	$185K	Hold	8,574	–	–	0.02%	145
2025 Q2	$176K	Hold	8,574	–	–	0.03%	139
2025 Q1	$234K	Hold	8,574	–	–	0.04%	142
2024 Q4	$280K	Hold	8,574	–	–	0.05%	143
2024 Q3	$195K	Hold	8,574	–	–	0.03%	153
2024 Q2	$319K	Hold	8,574	–	–	0.06%	146
2024 Q1	$486K	Hold	8,574	–	–	0.1%	131
2023 Q4	$679K	Hold	8,574	–	–	0.1%	202
2023 Q3	$592K	Hold	8,574	–	–	0.08%	253
2023 Q2	$939K	Hold	8,574	–	–	0.12%	211
2023 Q1	$918K	Hold	8,574	–	–	0.15%	167
2022 Q4	$733K	Hold	8,574	–	–	0.07%	195
2022 Q3	$574K	Hold	8,574	–	–	0.06%	222
2022 Q2	$640K	Hold	8,574	–	–	0.06%	196
2022 Q1	$1.25M	Hold	8,574	–	–	0.1%	163
2021 Q4	$2.91M	Buy	8,574 +41	+0.5%	+$15.9K	0.23%	79
2021 Q3	$3.73M	Hold	8,533	–	–	0.24%	98
2021 Q2	$2.98M	Hold	8,533	–	–	0.2%	109
2021 Q1	$3.12M	Buy	+8,533	New	+$3.51M	0.22%	104

Other funds holding CUE

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return

Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

LPC

Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Advisory Research's CUE Position: Q2 2026 in Review

Advisory Research reduced its Cue Biopharma (CUE) stake by 0.01% in Q2 2026, selling an estimated $23 and leaving 8,573 shares worth $271K. The position accounts for 0.03% of the portfolio, ranked #133.

Advisory Research first reported a position in CUE in Q1 2021 and has held it in 22 quarters since. The position peaked at $3.73M in Q3 2021. 49 funds tracked by Wall St. Rank hold CUE as of Q2 2026.

Advisory Research held 8,573 shares of Cue Biopharma worth $271K as of Q2 2026.
Advisory Research sold 1 Cue Biopharma share in Q2 2026, an estimated $23.
Cue Biopharma made up 0.03% of Advisory Research's portfolio in Q2 2026, its #133 holding.
Advisory Research first reported a position in Cue Biopharma in Q1 2021 and has held it in 22 quarters since.
Advisory Research's Cue Biopharma position peaked at $3.73M in Q3 2021.
49 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2026.

Based on Advisory Research's 13F filing for Q2 2026, filed 13 Aug 2026.